Takeda Pharma Files 13D/A Amendment on Phathom

TL;DR

Takeda updated its 13D filing for Phathom Pharmaceuticals on 4/10/24.

AI Summary

Takeda Pharmaceutical Co Ltd, through its subsidiary 03 Life Sciences, has filed an amendment (Amendment No. 7) to its Schedule 13D concerning Phathom Pharmaceuticals, Inc. The filing, dated April 10, 2024, indicates a change in the reporting of beneficial ownership. Takeda's address is listed as 1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku, Tokyo, Japan.

Why It Matters

This filing updates Takeda's stake and reporting obligations related to Phathom Pharmaceuticals, potentially signaling strategic shifts or ongoing investment in the company.

Risk Assessment

Risk Level: medium — Schedule 13D filings often relate to significant ownership stakes, which can indicate potential control changes or strategic interests that may impact stock price.

Key Players & Entities

• Takeda Pharmaceutical Co Ltd (company) — Filing entity
• Phathom Pharmaceuticals, Inc. (company) — Subject company
• 03 Life Sciences (company) — Subsidiary of Takeda
• Yoshihiro Nakagawa (person) — Contact person for Takeda
• Shashi Khiani (person) — Contact person at Polsinelli PC

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $10.66 — 04012024 Sale in Public Market 62,503 $10.66 $10.50 - $11.01 04052024 Sale in Publi
• $10.50 — 024 Sale in Public Market 62,503 $10.66 $10.50 - $11.01 04052024 Sale in Public Marke
• $11.01 — in Public Market 62,503 $10.66 $10.50 - $11.01 04052024 Sale in Public Market 144,471
• $10.78 — 04052024 Sale in Public Market 144,471 $10.78 $10.50 - $11.06 04082024 Sale in Publi
• $11.06 — n Public Market 144,471 $10.78 $10.50 - $11.06 04082024 Sale in Public Market 63,132
• $11.08 — 04082024 Sale in Public Market 63,132 $11.08 $10.88 - $11.29 04092024 Sale in Publi
• $10.88 — 024 Sale in Public Market 63,132 $11.08 $10.88 - $11.29 04092024 Sale in Public Marke
• $11.29 — in Public Market 63,132 $11.08 $10.88 - $11.29 04092024 Sale in Public Market 92,631
• $11.94 — 04092024 Sale in Public Market 92,631 $11.94 $10.98 - $12.25 1 The price reported
• $10.98 — 024 Sale in Public Market 92,631 $11.94 $10.98 - $12.25 1 The price reported in the
• $12.25 — in Public Market 92,631 $11.94 $10.98 - $12.25 1 The price reported in the column ti
• $1 — separate price. Each price was within a $1 price range, which such price range is

Filing Documents

• sc13da_041024.htm (SC 13D/A) — 47KB
• 0001395064-24-000025.txt ( ) — 49KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of the Prior Filing is hereby amended and restated in its entirety as follows

Item 5 of the Prior Filing is hereby amended and restated in its entirety as follows (a) See rows (11) and (13) of the cover page to this Amendment for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by the Reporting Person. (b) See rows (7) through (10) of the cover page to this Amendment for the number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. (c) Transactions in the shares of Common Stock effected by the Reporting Person during the 60 days prior to the date hereof are set forth on Schedule 1 and are incorporated herein by reference. (d) To the best knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Person. (e) On April 8, 2024, the Reporting Person ceased to be the beneficial owner of more than five percent of Common Stock. CUSIP No. 71722W107 Page 4 of 5 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated April 10, 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED By s Amit Singh Name Amit Singh Title Senior Vice President and Head of Treasury SCHEDULE 1 TRANSACTIONS IN THE SHARES OF COMMON STOCK BY THE REPORTING PERSON The following table sets forth all transactions in the shares of Common Stock effected by the Reporting Person during the past sixty (60) days. Unless otherwise noted below, all such transactions were effected in the open market through brokers and the price per share excludes commissions. Transaction Date Type of Transaction Number of Shares Sold Price Per Share Price Range 1 04012024 Sale in Public Market 62,503 $10.66 $10.50 - $1

View Full Filing

View this SC 13D/A filing on SEC EDGAR